Alexion Eyes Thrombosis Market For Next Soliris Patient Identification Push
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alexion is considering running a new program in the thrombosis market to identify potential paroxysmal nocturnal hemoglobinuria patients for Soliris, along the lines of the firm's ongoing EXPLORE diagnostics program looking for PNH in the bone marrow failure setting